These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 26627058)

  • 1. Antileishmanial, DNA Interaction, and Docking Studies of Some Ferrocene-Based Heteroleptic Pentavalent Antimonials.
    Rauf MK; Shaheen U; Asghar F; Badshah A; Nadhman A; Azam S; Ali MI; Shahnaz G; Yasinzai M
    Arch Pharm (Weinheim); 2016 Jan; 349(1):50-62. PubMed ID: 26627058
    [TBL] [Abstract][Full Text] [Related]  

  • 2. β-Sitosterol from Ifloga spicata (Forssk.) Sch. Bip. as potential anti-leishmanial agent against leishmania tropica: Docking and molecular insights.
    Majid Shah S; Ullah F; Ayaz M; Sadiq A; Hussain S; Ali Shah AU; Adnan Ali Shah S; Wadood A; Nadhman A
    Steroids; 2019 Aug; 148():56-62. PubMed ID: 31085212
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of antimony resistance markers in Leishmania tropica field isolates through a cDNA-AFLP approach.
    Kazemi-Rad E; Mohebali M; Khadem-Erfan MB; Saffari M; Raoofian R; Hajjaran H; Hadighi R; Khamesipour A; Rezaie S; Abedkhojasteh H; Heidari M
    Exp Parasitol; 2013 Oct; 135(2):344-9. PubMed ID: 23928349
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New thiophene-acridine compounds: Synthesis, antileishmanial activity, DNA binding, chemometric, and molecular docking studies.
    de Lima Serafim V; Félix MB; Frade Silva DK; Rodrigues KADF; Andrade PN; de Almeida SMV; de Albuquerque Dos Santos S; de Oliveira JF; de Lima MDCA; Mendonça-Junior FJB; Scotti MT; de Oliveira MR; de Moura RO
    Chem Biol Drug Des; 2018 Jun; 91(6):1141-1155. PubMed ID: 29415325
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of residual Sb(III) in meglumine antimoniate cytotoxicity and MRP1-mediated resistance.
    Dzamitika SA; Falcão CA; de Oliveira FB; Marbeuf C; Garnier-Suillerot A; Demicheli C; Rossi-Bergmann B; Frézard F
    Chem Biol Interact; 2006 Apr; 160(3):217-24. PubMed ID: 16524568
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pentavalent antimonials: new perspectives for old drugs.
    Frézard F; Demicheli C; Ribeiro RR
    Molecules; 2009 Jun; 14(7):2317-36. PubMed ID: 19633606
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insights into the trypanothione system in antimony-resistant and sensitive Leishmania tropica clinical isolates.
    Valashani HT; Ahmadpour M; Naddaf SR; Mohebali M; Hajjaran H; Latifi A; Salimi M; Farahmand M; Naeimi S; Raissi V; Kazemirad E
    Acta Trop; 2024 Jun; 254():107190. PubMed ID: 38508372
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antimonial drugs entrapped into phosphatidylserine liposomes: physicochemical evaluation and antileishmanial activity.
    Borborema SE; Osso Junior JA; Andrade Junior HF; Nascimento Nd
    Rev Soc Bras Med Trop; 2016 Apr; 49(2):196-203. PubMed ID: 27192589
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structural characterization and antileishmanial activity of newly synthesized organo-bismuth(V) carboxylates: experimental and molecular docking studies.
    Andleeb S; Imtiaz-Ud-Din ; Rauf MK; Azam SS; Haq IU; Tahir MN; Zaman N
    J Biol Inorg Chem; 2022 Feb; 27(1):175-187. PubMed ID: 34981207
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro anti-leishmanial activity of Prunus armeniaca fractions on Leishmania tropica and molecular docking studies.
    Shaheen N; Qureshi NA; Ashraf A; Hamid A; Iqbal A; Fatima H
    J Photochem Photobiol B; 2020 Dec; 213():112077. PubMed ID: 33220600
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gene expression analysis of antimony resistance in Leishmania tropica using quantitative real-time PCR focused on genes involved in trypanothione metabolism and drug transport.
    Mohebali M; Kazemirad E; Hajjaran H; Kazemirad E; Oshaghi MA; Raoofian R; Teimouri A
    Arch Dermatol Res; 2019 Jan; 311(1):9-17. PubMed ID: 30390113
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure-based virtual screening, molecular docking, ADMET and molecular simulations to develop benzoxaborole analogs as potential inhibitor against Leishmania donovani trypanothione reductase.
    Pandey RK; Kumbhar BV; Sundar S; Kunwar A; Prajapati VK
    J Recept Signal Transduct Res; 2017 Feb; 37(1):60-70. PubMed ID: 27147242
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Uptake and antileishmanial activity of meglumine antimoniate-containing liposomes in Leishmania (Leishmania) major-infected macrophages.
    Borborema SE; Schwendener RA; Osso JA; de Andrade HF; do Nascimento N
    Int J Antimicrob Agents; 2011 Oct; 38(4):341-7. PubMed ID: 21783345
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and antileishmanial activity of novel pyridinium-hydrazone derivatives.
    Alptuzun V; Cakiroglu G; Limoncu ME; Erac B; Hosgor-Limoncu M; Erciyas E
    J Enzyme Inhib Med Chem; 2013 Oct; 28(5):960-7. PubMed ID: 22803671
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and biological evaluation of ferrocenylquinoline as a potential antileishmanial agent.
    Yousuf M; Mukherjee D; Pal A; Dey S; Mandal S; Pal C; Adhikari S
    ChemMedChem; 2015 Mar; 10(3):546-54. PubMed ID: 25619822
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In-vitro sensitivity of Pakistani Leishmania tropica field isolate against buparvaquone in comparison to standard anti-leishmanial drugs.
    Jamal Q; Khan NH; Wahid S; Awan MM; Sutherland C; Shah A
    Exp Parasitol; 2015 Jul; 154():93-7. PubMed ID: 25911243
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Models of the putative antimony(V)-diolate motifs in antileishmanial pentavalent antimonial drugs.
    Lindquist-Kleissler B; Johnstone TC
    Dalton Trans; 2023 Jul; 52(27):9229-9237. PubMed ID: 37357833
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Susceptibility of Leishmania to novel pentavalent organometallics: Investigating impact on DNA and membrane integrity in antimony(III)-sensitive and -resistant strains.
    Islam A; do Prado BR; Dittz D; Rodrigues BL; Silva SMD; do Monte-Neto RL; Shabeer M; Frézard F; Demicheli C
    Drug Dev Res; 2024 May; 85(3):e22194. PubMed ID: 38704828
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of Leishmania donovani promastigote DNA topoisomerase I and human monocyte DNA topoisomerases I and II by antimonial drugs and classical antitopoisomerase agents.
    Walker J; Saravia NG
    J Parasitol; 2004 Oct; 90(5):1155-62. PubMed ID: 15562618
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-leishmanial activity of heteroleptic organometallic Sb(v) compounds.
    Ali MI; Rauf MK; Badshah A; Kumar I; Forsyth CM; Junk PC; Kedzierski L; Andrews PC
    Dalton Trans; 2013 Dec; 42(48):16733-41. PubMed ID: 24077559
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.